Skip to main content

Table 4 Toxicity per cycle and per patient

From: Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience

Toxicity Per cycle (n = 169) Per patient (n = 33)
Hematological Grade 2 Grade 3 Grade 4 Grade 2 Grade 3 Grade 4
  No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Leucopenia 51 (30) 31 (18) 9 (5) 11 (33) 6 (18) 8 (24)
Neutropenia 11 (6) 22 (13) 60 (36) 2 (6) 5 (15) 18 (54)
Thrombocytopenia 12 (7) 4 (2) 0 5 (15) 4 (12) 0
Anemia 26 (15) 5 (3) 0 12 (36) 2 (6) 0
Non hematological       
  No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Nausea/vomiting 14 (9) 2 (1) 0 9 (27) 1 (3) 0 (0)
Diarrhea 8 (5) 1 (1) 1 (1) 7 (21) 1 (3) 1 (3)
Stomatitis 14 (8) 1 (1) 0 7 (21) 1 (3) 0
Neurosensory 14 (8) 0 0 6 (18) 0 0
Fever 16 (9) 0 0 8 (24) 0 0
Infection 2 (1) 0 0 1 (3) 0 0
Thromboembolism 2 (1) 0 0 2 (6) 0 0
Hypersensitivity 1 (1) 0 0 1 (3) 0 0